Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02169336 · ClinicalTrials.gov registry record · Phase 2
Placebo-Controlled Evaluation of Intranasal Dexmedetomidine for Postoperative Analgesia Following Bunionectomy
A Phase 2 study, sponsored by Baudax Bio.
- Terminated
- Registry status
- Phase 2
- Development phase
- 95
- Enrollment target
NCT02169336 is a Phase 2 study that was terminated before completion, run by Baudax Bio. The registered enrollment target is 95 participants.
The verdict
NCT02169336, a Phase 2 study, was terminated before completion, sponsored by Baudax Bio.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 95 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the analgesic efficacy of two dose levels of DEX-IN compared with placebo, using the summed pain intensity difference over the first 48 hours (SPID48) in subjects with acute moderate to severe pain following unilateral bunionectomy.
Interventions
- OTHER Intranasal Placebo
- DRUG Intranasal Dexmedetomidine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 95 participants |
| Start Date | 2014-06 |
| Est. Completion | 2014-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02169336
The ClinicalTrials.gov registry entry for NCT02169336 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 95 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baudax Bio, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Intranasal Placebo is the first listed.
NCT02169336 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02169336 about?
NCT02169336 is a clinical study titled "Placebo-Controlled Evaluation of Intranasal Dexmedetomidine for Postoperative Analgesia Following Bunionectomy". The primary objective of this study is to evaluate the analgesic efficacy of two dose levels of DEX-IN compared with placebo, using the summed pain intensity difference over the first 48 hours (SPID48) in subjects with acute moderate to severe pain following unilateral bunionectomy.
What is the current status of trial NCT02169336?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 95 participants. The study started on 2014-06. Estimated completion is 2014-10.
What interventions are being tested in trial NCT02169336?
The interventions under investigation include: Intranasal Placebo (OTHER), Intranasal Dexmedetomidine (DRUG).
Who is sponsoring clinical trial NCT02169336?
This trial is sponsored by Baudax Bio, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.